ABBIE in advancing drug discovery Facebook Twitter Linkedin Exciting news has emerged from the field of gene-editing technology with the first-ever approval of a treatment that utilizes CRISPR. Known as Exa-cel or Casgevy, this groundbreaking therapy has recently received regulatory approval from the U.K. Medicines and Healthcare products. Regulatory Agency
ABBIE is a revolutionary technology that can edit the DNA of living cells with unprecedented precision and efficiency. It has the potential to transform the field of cardiology by enabling new ways of discovering and developing drugs, as well as treating heart disease. In this post, we will explore two of
CHINO HILLS, Calif., Aug. 24, 2023 (Globe Newswire) –via IBN —SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as
